AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02170324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Study NCT04042896 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treadmill exercise
Description: traditional aerobic exercise
Study NCT02388919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
Study NCT02170324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01259102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
Study NCT00495495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone treatment
Description: Ozone treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three, Six and Nine-Month visits.
Study NCT00495495 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Placebo treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three-, Six- and Nine-Month visits.
Study NCT02458690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues (BtB)
Description: BTB is a widely used, empirically supported, stand-alone CBT program for depression designed for primary care patients and appropriate for adults with little computer experience and a 5th-6th grade reading level. BtB utilizes an interactive, multimedia format to deliver eight 50-minute, weekly therapy sessions. Although sessions are tailored to each patient's problems, general topics include challenging dysfunctional thoughts, activity scheduling, problem solving, graded exposure, task breakdown, sleep management, and relapse prevention. Patients are also assigned tailored homeworks that are customized to their needs and reviewed at the start of each session.
Study NCT02458690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Treatment in Primary Care (PST-PC)
Description: PST-PC is a manualized, empirically supported CBT developed for use by healthcare professionals in primary care. The focus of the 6-10 30-minute sessions is teaching patients approaches for solving current problems contributing to depression. We are delivering PST-PC via telephone.
Study NCT02458690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Medications
Description: The IMPACT treatment manual provides guidelines for using antidepressants, such as selecting a medication, titrating, switching to another medication, managing side effects, and avoiding drug interactions. To optimize eIMPACT for CVD risk reduction, we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These medications are FDA approved for the treatment of depression and are the safest from a cardiovascular perspective.
Study NCT02458690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients randomized to usual primary care for depression are informed of their depression diagnosis, encouraged to follow-up with their Eskenazi Health primary care provider, and provided a list of local mental health services. The patient's primary care provider will receive a letter indicating that their patient has a depressive disorder and was randomized to usual care. This letter also provides a list of local mental health services. Like those in the intervention group, usual care patients continue to have access to services that are part of usual care in the targeted systems. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
Study NCT04023513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein intake
Description: 6 weeks of high protein intake mainly via food (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
Study NCT04023513 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control, no intervention
Description: No Intervention, control
Study NCT04023513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low protein intake
Description: 6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
Study NCT04023513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: 6 weeks of different protein intake followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
Study NCT01682629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Physical Realism Simulation
Description: High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create high physical realism (HiR), full simulator functions were activated (turned on) including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. Low physical realism (LoR) groups had the identical simulator but the compressor was turned off, thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups.
Study NCT04204811 — intervention group
Intervention type: OTHER
Intervention: Prehabilitation
Description: A program of personalized independent home exercises are outline for participants to complete daily. Prehabilitation coaching will continue weekly until admission for surgical tumor debulking or termination of neoadjuvant treatment for any reason.
Study NCT02388919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Basic dosage, take once when limosis in the morning.
Study NCT00005044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex
Description: Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.
Study NCT00005044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eulexin
Description: Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.
Study NCT00005044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: LHRH agonist of choice. The manufacturer's instructions should be followed.
Study NCT00005044 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: \[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)\] OR \[regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin\]
Study NCT01523587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
Study NCT01523587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: erlotinib taken once daily
Study NCT02113371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Study NCT01216657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
Study NCT04952831 — intervention group
Intervention type: OTHER
Intervention: diffusion MRI (dMRI)
Description: All participants underwent dMRI scan at baseline
Study NCT01594047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine infusion
Description: Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery
Study NCT01594047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone PCA
Description: Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)
Study NCT00201916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5250 cGy/20 fractions over 28 days
Description: see above
Study NCT01086085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: Adefovir 10 mg po once daily for 36 weeks
Study NCT00201916 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6600 cGy/33 fractions over 45 days
Description: see above
Study NCT01086085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [PEGASYS]
Description: Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
Study NCT00314977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)
Study NCT01086085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [PEGASYS]
Description: Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
Study NCT01086085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [PEGASYS]
Description: Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
Study NCT03757156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Withdrawal of aspirin
Description: People who are taking aspirin stop to taking aspirin.
Study NCT04937231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: For Week 1 and 2 : Treadmill 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 10-20 minutes For Week 3 and 4; Cycle ergometer 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 30-40 minutes
Study NCT04937231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercises
Description: For Week 1 and 2; 2 x 10 rep (unilateral leg press) 4x 12 reps (Bilateral leg press~1 x 8 rep ( unilateral arm curls For Week 3 and 4; 1 x 10 reps Shoulder press~1 x15 rep Bilateral knee extension~1 x 10 reps Bilateral arm curls
Study NCT04937231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined training
Description: For Week 1 and 2; Aerobic exercise on Treadmill along with dumbbell to perform upper limb exercises (biceps curls, side curls extensions, upright row, back fly) and used Thera band to perform lower limb exercises for 10-20 minutes For Week 3 and 4; Aerobic exercise on Treadmill along with dumbbell and Thera band to perform upper limb and lower limb exercises for 30-40 minutes
Study NCT04721730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLH-YC
Description: There will be 5 weekly 2-hour sessions. The optimised PLH-YC uses a participatory, non-didactic approach to engage parents. Parents learn positive parenting skills and how to manage child behaviour problems. The program includes Session 1: One-on-One Time and Say What You See, Session 2: Praise and Rewards, Session 3: Instructions, Redirect, Rules, and Routines, Session 4: Ignore and Consequences, Session 5: Reflection and Moving On. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
Study NCT04721730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lecture
Description: Lecture on parenting. This is a 26-slides power-point presentation that was developed by the University of Bremen for the purpose of this study. Duration: 1 to 1.5 hours. Content: 1) Stages of child development; (2) Potential risk factors for child emotional or behaviour problems; (3) Resources and protective factors; (4) Tips: What parents can do to promote children's development.
Study NCT03475823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sideritis Scardica
Description: Sideritis Scardica is a popular, naturally un-caffeinated Eastern European tea extract derived from the ironwort plant
Study NCT01352182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride
Description: Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.
Study NCT03475823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba
Description: Ginkgo biloba is an extract from the ginkgo tree comprising ginkgolides and bilobalide. In this trial Ginkgo acted as an active control.
Study NCT03475823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: An inert encapsulated powder provided by Finzelberg.
Study NCT03092882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Program
Description: The Diabetes Self-Management Program is a platform that includes a smart meter, access to coaching 24/7, and a mobile app and website that help members manage their diabetes. The program offers diabetes education and coaching delivered entirely through the smart meter and mobile app or website.
Study NCT00314977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)
Study NCT00314977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
Study NCT01876498 — intervention group
Intervention type: PROCEDURE
Intervention: Xiaflex surgery
Description: Xiaflex surgery
Study NCT05509348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 1: ADAPT Workshop
Description: 2 day workshop
Study NCT05509348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 1: ADAPT Online
Description: Online curriculum
Study NCT05509348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2: ADAPT Group
Description: 3 in person group sessions
Study NCT05509348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2: ADAPT Individual
Description: 3 sessions in person one on one
Study NCT02004158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive psychology intervention
Study NCT02056938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulins treatment
Study NCT02056938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab treatment
Study NCT01190319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strawberry Beverage
Description: Beverage, daily for 8 weeks, 12g freeze-dried strawberry powder
Study NCT01190319 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo beverage, 8 weeks
Study NCT01225952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crystalens AO
Description: Bausch \& Lomb model silicone multi-piece accommodating IOL.
Study NCT01225952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReSTOR 3.0
Description: An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
Study NCT01225952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO Tecnis Multifocal
Description: The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.
Study NCT05058326 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Portable endoanal manometry
Description: Endoanal manometry values will be obtained using de Anopress® device. Fecal incontinence severity questionaries will be filled and collected.
Study NCT05058326 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endoanal ultrasound
Description: To assess the integrity of the anal canal.
Study NCT05058326 — intervention group
Intervention type: OTHER
Intervention: Incontinence severity scale questionaires
Description: Wexner and St. Mark's scales.
Study NCT02932202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Longitudinal Nutritional Counseling
Study NCT02932202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Study NCT03892070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)
Description: 1.5 g of HMB will be provided for 12 weeks twice daily
Study NCT03892070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: 1.5 g twice daily for 12 weeks
Study NCT00006111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT01967186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraportal islet transplantation
Study NCT01967186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramuscular islet transplantation
Study NCT01967186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramuscular transpl with stemcells
Study NCT01967186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Description: All patients will undergo kidney transplantation regardless of arm
Study NCT01967186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney transplantation
Description: All patients will undergo kidney transplantation regardless of arm
Study NCT02529696 — intervention group
Intervention type: DEVICE
Intervention: Accelerometer
Description: Measures patient movement
Study NCT02806518 — intervention group
Intervention type: PROCEDURE
Intervention: DIRT
Description: An infrared camera is used to capture video sequences of thermal images before, during and after exposure of the lower abdomen to a cold challenge.
Study NCT04663464 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS
Description: Single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes
Study NCT04663464 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide-SC
Description: Single-dose administration of abaloparatide 80 μg subcutaneous injection to the periumbilical region of the abdomen
Study NCT00888108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: 150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
Study NCT00888108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
Study NCT00015990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study NCT00015990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02932709 — intervention group
Intervention type: BEHAVIORAL
Intervention: suicide attempt
Description: suicide attempt : We evaluated the effectiveness of telephone follow-up of patients who had referred to an emergency psychiatric unit for attempted suicide on any further attempt/s over the following year.
Study NCT03510091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: A video will be shown to parents of patients ages 9-18 that review HPV transmission, relation to cancer, role of immunization, myths, side effects, series timing and need for completion. All parents or legal guardians of patients will be given the option to proceed with HPV vaccination, decline, or discuss further with their provider
Study NCT01807546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib
Description: Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
Study NCT01820195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral N-Acetyl Cystein
Description: Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast
Study NCT01820195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV N-Acetyl Cystein
Description: Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration
Study NCT01820195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The patients in this group will be received both oral placebo and IV placebo
Study NCT02131324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD06 Cream
Study NCT02131324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol Propionate Cream 0.05%
Study NCT01424332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darexaban
Description: oral
Study NCT01424332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid (ASA)
Description: oral